PT  - JOURNAL ARTICLE
AU  - Vermeulen, C.
AU  - Pagès-Gallego, M.
AU  - Kester, L.
AU  - Kranendonk, M.E.G.
AU  - Wesseling, P.
AU  - van der Lugt, J.
AU  - van Baarsen, K.
AU  - Hoving, E.W.
AU  - Tops, B.B.J.
AU  - de Ridder, J.
TI  - Ultra-fast deep-learned pediatric CNS tumor classification during surgery
AID  - 10.1101/2023.01.25.23284813
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.01.25.23284813
4099  - http://medrxiv.org/content/early/2023/01/27/2023.01.25.23284813.short
4100  - http://medrxiv.org/content/early/2023/01/27/2023.01.25.23284813.full
AB  - The primary treatment of CNS tumors starts with a neurosurgical resection in order to obtain tumor tissue for diagnosis and to reduce tumor load and mass effect. The neurosurgeon has to decide between radical resection versus a more conservative strategy to prevent surgical morbidity. The prognostic impact of a radical resection varies between tumor types. However due to a lack of pre-operative tissue-based diagnostics, limited knowledge of the precise tumor type is available at the time of surgery. Current standard practice includes preoperative imaging and intraoperative histological analysis, but these are not always conclusive. After surgery, histopathological and molecular tests are performed to diagnose the precise tumor type. The results may indicate that an additional surgery is needed or that the initial surgery could have been less radical. Using rapid Nanopore sequencing, a sparse methylation profile can be directly obtained during surgery, making it ideally suited to enable intraoperative diagnostics. We developed a state-of-the-art neural-network approach called Sturgeon, to deliver trained models that are lightweight and universally applicable across patients and sequencing depths. We demonstrate our method to be accurate and fast enough to provide a correct diagnosis with as little as 20 to 40 minutes of sequencing data in 45 out of 49 pediatric samples, and inconclusive results in the other four. In four intraoperative cases we achieved a turnaround time of 60-90 minutes from sample biopsy to result; well in time to impact surgical decision making. We conclude that machine-learned diagnosis based on intraoperative sequencing can assist neurosurgical decision making, allowing neurological comorbidity to be avoided or preventing additional surgeries.Competing Interest StatementJdR, MPG and CV are inventors on a patent covering the development of sturgeon. JdR is co-founder and director of Cyclomics, a genomics company.Funding Statementthis project was partially funded by the Oncode Institute technology development fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research was approved by the Biobank and Data access committee (BDAC) of the Princess Máxima Center for pediatric oncology. All included patients provided written informed consent for participation in the biobank (International Clinical Trials Registry Platform: NL7744). Inclusion of intraoperative samples was ethically approved via the same decision; the results were not shared with caregivers and therefore not used to alter patient treatment nor diagnosis.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available via the EGA repository upon publication.